SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) will release first quarter 2026 financial results before U.S. markets open on Tuesday, May 5, 2026. A conference call to discuss results and business outlook begins at 8:00 a.m. EDT / 2:00 p.m. CET and will be webcast live.

A replay of the webcast will be available on the company's investor relations website after the call.

News Market Reaction – SOPH

-1.35%

-1.35% Session close to close

In the Apr 21 session, SOPH declined 1.35%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timeline for Q1 2026 results, confirming a release before market open on ...

Analysis

This announcement sets the timeline for Q1 2026 results, confirming a release before market open on May 5, 2026 with an 8:00 a.m. EDT conference call. Recent history shows SOPHiA GENETICS delivering double-digit revenue growth to $77.3M in 2025 but with a $79.0M IFRS net loss. Investors may watch for updates versus 2026 revenue guidance of $92M–$94M, margin trends, and any use of the F-3 registered warrant structure.

Key Figures

Q4 2025 revenue: $21.7M FY 2025 revenue: $77.3M Q4 revenue growth: 22% +5 more

8 metrics

Q4 2025 revenue $21.7M Q4 2025, +22% YoY

FY 2025 revenue $77.3M Full-year 2025, +19% YoY

Q4 revenue growth 22% Q4 2025 YoY revenue growth

FY revenue growth 19% Full-year 2025 YoY revenue growth

Adjusted gross margin 74.2% Full-year 2025

IFRS net loss $79.0M Full-year 2025

2026 revenue guidance $92M–$94M Company guidance for 2026 revenue

Warrant exercise price $5.1829 Exercise price for 75,000 F-3 registered shares

Previous Earnings date Reports

1 past event · Latest: Feb 17 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 17	Earnings date notice	Neutral	+0.2%	Announced Q4 and full-year 2025 results date with webcast conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings date news on Feb 17, 2026 coincided with a modest positive move of 0.21%, suggesting past date announcements have been low-volatility events.

Recent Company History

Over recent months SOPHiA GENETICS combined commercial and financial milestones with modest stock reactions. Collaborations, such as the Mount Sinai precision cancer care agreement on Apr 16, 2026, and U.S. network expansion to serve up to 60,000 patients annually, highlighted growth in its SOPHiA DDM™ platform. Financially, Q4 and full-year 2025 results on Mar 3, 2026 showed double-digit revenue growth but ongoing losses. The current Q1 2026 earnings-date notice continues the pattern of scheduled communications around results and outlook.

Key Terms

f-3, rule 10b5-1, form 144, form 4, +2 more

6 terms

f-3 regulatory

"SOPHiA GENETICS files an F-3 to register up to 75,000 ordinary shares"

Form F-3 is a U.S. Securities and Exchange Commission registration form that allows qualifying foreign issuers to pre-clear and quickly sell new securities under a shelf registration — essentially a pre-approved plan to issue shares or bonds when needed. For investors it matters because it speeds a company’s ability to raise cash, which can increase the supply of securities and potentially dilute existing holdings or change financing costs and ownership stakes.

rule 10b5-1 financial

"multiple Rule 10b5-1 open-market sales by Manuela Valente"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

form 144 regulatory

"SOPHiA GENETICS SA SEC Filing (Form 144) reports a notice to sell"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

View in glossary

form 4 regulatory

"[Form 4] SOPHiA GENETICS SA Insider Trading Activity"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

View in glossary

restricted stock units financial

"reports a notice to sell 380 restricted stock units of Common Stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

ordinary shares financial

"reported an open-market sale of 600 ordinary shares on April 14, 2026"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON and ROLLE, Switzerland, April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the first quarter 2026 before U.S. markets open on Tuesday, May 5, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.

The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the website after its completion.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a software company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform that analyzes complex multimodal data – including genomics, radiomics, clinical, biological, and digital pathology data – to generate real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-to-announce-financial-results-for-first-quarter-2026-on-may-5-2026-302743779.html

SOURCE SOPHiA GENETICS

FAQ

When will SOPH report its Q1 2026 results and what time is the call?

SOPH will report Q1 2026 results before U.S. markets open on May 5, 2026. According to the company, a conference call begins at 8:00 a.m. EDT / 2:00 p.m. CET to discuss results and outlook, followed by a webcast replay.

How can investors access the SOPHiA GENETICS (SOPH) May 5, 2026 earnings webcast?

Investors can access the live webcast via the company's investor relations website. According to the company, the call will be webcast live and a replay will be posted on the same investor relations page after the event.

What will be covered on SOPHiA GENETICS' May 5, 2026 conference call (SOPH)?

The call will cover first quarter 2026 financial results and the company's business outlook. According to the company, management will discuss performance metrics and provide commentary on near-term strategic priorities during the webcast.

Will there be a replay available after the SOPH Q1 2026 earnings call on May 5?

Yes, a replay will be available on the investor relations website after the call concludes. According to the company, the webcast replay will remain accessible for investors who cannot join the live conference call.

What time is the SOPH investor call for international attendees on May 5, 2026?

For international attendees, the call starts at 2:00 p.m. CET on May 5, 2026. According to the company, that corresponds to 8:00 a.m. EDT, and the event will be webcast live for global access.